Bristol-Myers Squibb Company ($BMY) Stock Forecast: Up 5.1% Today

What is Bristol-Myers Squibb Company?

Bristol Myers Squibb Company ($BMY) is a pharmaceutical company recognized for its innovative treatments across various therapeutic areas. Today, the stock demonstrated a significant bullish movement in the market.

Why is Bristol-Myers Squibb Company going up?

BMY stock is up 5.1% on Jan 6, 2026 16:16

• A recent collaboration between Gilead and OncoNano Medicine utilizing OncoNano's drug delivery platform may have attracted investor interest in the pharmaceutical sector, benefiting companies like Bristol Myers Squibb.
• Robeco Institutional Asset Management B.V. raised its stake in BMY by 6.4% during the 3rd quarter, indicating a growing confidence in the company's future prospects, potentially influencing the bullish movement.
• Despite some reduction in BMY position by D.A. Davidson & CO., the overall positive sentiment towards the company, especially post exceeding earnings estimates and offering strong guidance, likely overshadowed this sell-off.
• The comparison between Zenas Biopharma's obexelimab and Amgen's Uplizna in the Phase 3 trial may have highlighted Bristol Myers Squibb's competitive edge or potential in the pharmaceutical market, fueling investor optimism and driving the stock price upwards.

BMY Price Chart

BMY Technical Analysis

BMY News

Gilead Keeps Dealing With $300M OncoNano Drug Delivery Cancer Pact

Gilead is collaborating with OncoNano Medicine in a deal worth up to $300 million to utilize OncoNano's ON-BOARD platform for delivering one of Gilead's investigational cancer drugs. The ON-BOARD platform uses pH-sensitive micelles to precisely deliver drugs to tumors while preventing systemic exposure. This partnership aligns with Gilead's stated commitment to active business development, particularly following the discontinuation of its TIGIT therapy domvanalimab.

https://www.biospace.com/deals/gilead-keeps-dealing-with-300m-onconano-drug-delivery-cancer-pact

Robeco Institutional Asset Management B.V. Acquires 409,231 Shares of Bristol Myers Squibb Company $BMY

Robeco Institutional Asset Management B.V. has increased its stake in Bristol Myers Squibb Company ($BMY) by 6.4%, acquiring an additional 409,231 shares during the 3rd quarter. This brings their total holdings to 6,810,632 shares, valued at $307.16 million, representing 0.33% of the company. Other institutional investors also adjusted their positions in BMY, which recently announced a quarterly dividend increase.

https://www.marketbeat.com/instant-alerts/filing-robeco-institutional-asset-management-bv-acquires-409231-shares-of-bristol-myers-squibb-company-bmy-2026-01-06/

Bristol Myers Squibb Company $BMY Position Decreased by D.A. Davidson & CO.

D.A. Davidson & CO. has significantly reduced its stake in Bristol Myers Squibb (NYSE:BMY) by 22.7%, selling 78,288 shares and retaining 266,519 shares valued at approximately $12.02 million. This comes as Bristol Myers Squibb increased its quarterly dividend to $0.63, yielding around 4.7%, and analysts maintain a consensus "Hold" rating with a $54.62 price target. The company recently reported quarterly earnings that topped estimates and issued FY 2025 guidance.

https://www.marketbeat.com/instant-alerts/filing-bristol-myers-squibb-company-bmy-position-decreased-by-da-davidson-co-2026-01-06/

Is Bristol-Myers Squibb Company's (NYSE:BMY) 33% ROE Better Than Average?

Bristol-Myers Squibb Company (NYSE:BMY) boasts a 33% Return on Equity (ROE), which is higher than the Pharmaceuticals industry average of 22%. While this indicates strong profitability in relation to its equity capital, the analysis highlights that the company also uses a high level of debt with a debt-to-equity ratio of 2.63, which can inflate ROE but also introduces risk. The article suggests considering other factors like profit growth forecasts in addition to ROE and debt levels when evaluating the stock.

https://finance.yahoo.com/news/bristol-myers-squibb-companys-nyse-130015922.html

Zenas Bio Inflammation Drug Meets Phase 3 Goals, But Is It Enough to Compete With Amgen?

Zenas Biopharma's obexelimab met its primary and secondary endpoints in a Phase 3 trial for immunoglobulin G4-related disease (IgG4-RD), demonstrating a statistically significant and clinically meaningful reduction in flares. While the drug showed a 56% reduction in flares, this is lower than the 87% reduction achieved by Amgen's Uplizna in a similar study. Zenas aims to differentiate obexelimab, an injectable therapy, through its potential for long-term maintenance and patient self-administration, despite the competitive results.

https://medcitynews.com/2026/01/zenas-biopharma-inflammation-obexelimab-b-cell-rare-disease-igg4-rd-zbio/

Trending Today

Corn ($CORN) Commodity Forecast: Down 5.3% Today

Williams-Sonoma Inc. (DE) ($WSM) Stock Forecast: Up 5.0% Today

MicroVision Inc. ($MVIS) Stock Forecast: Up 6.0% Today

Riot Platforms, Inc. ($RIOT) Stock Forecast: Up 5.7% Today

Hims & Hers Health Inc. ($HIMS) Stock Forecast: Up 6.5% Today

Natural Gas ($GAS) Commodity Forecast: Up 5.1% Today

Enphase Energy Inc. ($ENPH) Stock Forecast: Up 5.8% Today

Five Below Inc. ($FIVE) Stock Forecast: Up 5.4% Today

DexCom Inc. ($DXCM) Stock Forecast: Up 5.3% Today

Novavax Inc. ($NVAX) Stock Forecast: Up 5.2% Today

Bristol-Myers Squibb Company Price History

01.09.2025 - BMY Stock was up 5.5%

• The bullish movement in BMY could be attributed to investors favoring its growth potential despite facing generic headwinds.
• The comparison with Merck (MRK) might have highlighted BMY's resilience and potential for future success, leading to increased investor confidence.
• The market's positive response indicates that BMY's strategic initiatives and focus on new treatments are resonating well with investors, driving the stock price higher.

03.11.2025 - BMY Stock was up 5.5%

• Bristol Myers Squibb's stock surged by approximately 6% after announcing a delay in the readout of a crucial Phase 3 clinical trial for its drug Cobenfy, designed for Alzheimer's disease psychosis. The market reacted positively to this unexpected news, indicating investor optimism about the drug's potential success.
• The decision to enroll more patients in the clinical trial demonstrates the company's commitment to ensuring data integrity and addressing unmet medical needs in Alzheimer's disease, further boosting investor confidence in Bristol Myers Squibb.
• Additionally, the successful achievement of a drug discovery milestone in collaboration with Terray Therapeutics showcases Bristol Myers Squibb's dedication to leveraging innovative technologies like AI to accelerate drug discovery processes, potentially leading to the development of novel and effective treatments.
• The continuation of the ADEPT-2 Phase 3 study in psychosis associated with Alzheimer's Disease, despite site irregularities, underlines Bristol Myers Squibb's adherence to rigorous clinical standards and its proactive approach to resolving challenges in clinical trials, reinforcing investor trust in the company's research and development efforts.

03.11.2025 - BMY Stock was up 5.1%

• BMY's stock surged after a positive update on its late-stage clinical trial for treating psychosis associated with Alzheimer’s disease, signaling progress in its research endeavors.
• A collaboration milestone with Terray Therapeutics highlights BMY's utilization of AI-enabled drug discovery technologies to accelerate small molecule drug development, potentially enhancing investor confidence.
• Despite delays in the Adept-2 study for Cobenfy in Alzheimer's psychosis, efforts to rectify site irregularities and continue enrolling new patients demonstrate BMY's commitment to upholding clinical standards and addressing medical needs, possibly contributing to the stock's bullish performance.

05.00.2026 - BMY Stock was down 1.7%

• Increased investments by Railway Pension Investments Ltd and CWA Asset Management Group LLC in Bristol Myers Squibb (BMY) may have hinted at uncertainties about the company's future performance, influencing the bearish trajectory.
• While Bristol Myers Squibb exceeded Q3 earnings and revenue projections and raised its dividend, market sentiments may have been dampened by apprehensions regarding the company's growth outlook.
• Favorable results from Zenas BioPharma's Phase 3 trial and the thriving Hair Loss Treatment Market could have drawn investor attention away from Bristol Myers Squibb, impacting its stock trajectory.
• The optimistic forecast for the pharmaceutical sector, evidenced by growth prospects in the aminoglycosides market, might have steered investor focus elsewhere from Bristol Myers Squibb, contributing to the downward movement in its stock.

14.10.2025 - BMY Stock was down 5.5%

• Despite strong performance in the third quarter, Bristol Myers Squibb experienced a bearish movement, possibly due to profit-taking by investors after a recent 7.2% increase in share price.
• Jim Cramer's decision to back off on Bristol-Myers might have influenced investor sentiment, leading to a sell-off in the stock.
• The market may be shifting focus towards other promising opportunities like Baidu and Alibaba, as mentioned by Jim Cramer, diverting attention away from Bristol-Myers Squibb in the short term.

30.09.2025 - BMY Stock was up 5.0%

• Investors are optimistic about BMY's upcoming Q3 earnings, expecting a boost from the rising demand for new therapies like Opdivo and Camzyos.
• The market movement reflects confidence in BMY's ability to navigate through declines in legacy-drug sales by focusing on its newer, more promising treatments.
• The bullish trend suggests that investors may be considering buying or holding BMY stock in anticipation of positive earnings results driven by the success of its innovative therapies.

30.09.2025 - BMY Stock was up 5.0%

• BMY saw a positive uptrend after surpassing Q3 earnings and sales expectations, boosted by the success of key drugs including Opdivo, Reblozyl, and Breyanzi.
• The decision to increase its 2025 sales forecast despite decreases in older drugs demonstrates confidence in its newer treatments and overall growth strategy.
• Market sentiment is favorable towards BMY's performance, especially as the growing demand for cutting-edge medications like Opdivo and Camzyos offsets declines in older products.

03.09.2025 - BMY Stock was down 5.0%

• BMY stock price dropped by 3.58% in the current session, continuing its downward trend over the past month and year.
• The Price Over Earnings overview indicates a decline in the stock's performance, possibly raising concerns among long-term shareholders.
• The bearish movement could be attributed to various factors such as disappointing earnings reports, regulatory setbacks, or broader market conditions impacting the pharmaceutical sector.

06.00.2026 - BMY Stock was up 5.1%

• A recent collaboration between Gilead and OncoNano Medicine utilizing OncoNano's drug delivery platform may have attracted investor interest in the pharmaceutical sector, benefiting companies like Bristol Myers Squibb.
• Robeco Institutional Asset Management B.V. raised its stake in BMY by 6.4% during the 3rd quarter, indicating a growing confidence in the company's future prospects, potentially influencing the bullish movement.
• Despite some reduction in BMY position by D.A. Davidson & CO., the overall positive sentiment towards the company, especially post exceeding earnings estimates and offering strong guidance, likely overshadowed this sell-off.
• The comparison between Zenas Biopharma's obexelimab and Amgen's Uplizna in the Phase 3 trial may have highlighted Bristol Myers Squibb's competitive edge or potential in the pharmaceutical market, fueling investor optimism and driving the stock price upwards.

31.06.2025 - BMY Stock was down 5.6%

• Bristol-Myers Squibb (BMY) stock had a bearish movement today, potentially attributed to investors taking a cautious stance ahead of the company's Q2 earnings release.
• The expectations for BMY's Q2 results, where growth drugs are forecasted to offset some declines, may have caused uncertainty among investors, leading to the bearish trend.
• With the earnings report eagerly awaited, investors are likely adopting a "wait and see" strategy, adding to the downward pressure on BMY stock.
• While tech giants like Apple and Amazon are in the spotlight today, the pharmaceutical sector, represented by BMY, appears to be garnering a more subdued market reaction.

31.06.2025 - BMY Stock was down 5.9%

• Bristol-Myers Squibb posted Q2 revenue of $12.27 billion, exceeding expectations. However, their EPS of $1.46 missed the consensus of $1.58, leading to disappointment among investors.
• The company's decision to reduce the 2025 EPS guidance to $6.35-$6.65 could have influenced the market sentiment, despite an increase in the sales forecast to $46.5 billion-$47.5 billion.
• Uncertainties regarding the company's future performance, including the challenges of new product launches alongside declining legacy products, may be prompting investors to adopt a more cautious stance, resulting in the stock's downward trajectory on the latest trading day.

31.06.2025 - BMY Stock was down 5.4%

• BMY posted robust Q2 earnings and sales figures, surpassing expectations – typically prompting a bullish market response. However, missing EPS estimates and reducing the 2025 EPS guidance likely led to the bearish outlook.
• Uncertainty surrounding the company's future earnings potential may have triggered the negative market reaction, despite a positive sales forecast.
• Investors could be exercising caution due to conflicting analyst recommendations, with some advising to adopt a wait-and-see strategy before the Q2 results.
• The bearish movement in BMY's stock today might have been influenced by the overall market sentiment towards pharmaceutical stocks and broader economic conditions.